CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash Flows from Operating Activities:
Net income	$ 34,389	$ 28,659
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	13,139	14,662
Provision for doubtful accounts	18,078	13,664
Non-cash compensation	11,788	12,556
401(k) employer match	6,547	5,134
(Gain) loss on disposal of property and equipment	(22)	556
Deferred income taxes	17,228	18,689
Equity in earnings of equity method investments	(3,149)	(3,602)
Amortization of deferred debt issuance costs	555	555
Return on equity investment	4,656	1,913
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable	(28,924)	(46,107)
Other current assets	(5,896)	870
Other assets	(12,202)	(11,909)
Accounts payable	(5,430)	7,308
Securities Class Action Lawsuit settlement accrual, net	0	0
Accrued expenses	22,584	(9,100)
Other long-term obligations	201	(150)
Net cash provided by operating activities	73,542	33,698
Cash Flows from Investing Activities:
Proceeds from sale of deferred compensation plan assets	622	230
Proceeds from the sale of property and equipment	118	0
Purchases of deferred compensation plan assets	0	0
Purchase of investment	(436)	(750)
Purchases of property and equipment	(9,074)	(13,502)
Acquisitions of businesses, net of cash acquired	(24,128)	(31,378)
Net cash used in investing activities	(32,898)	(45,400)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options and warrants	4,214	0
Proceeds from issuance of stock to employee stock purchase plan	1,798	1,818
Shares withheld upon stock vesting	(6,454)	0
Tax benefit from stock options exercised and restricted stock vesting	0	7,241
Non-controlling interest distribution	(216)	(284)
Sale of noncontrolling interest	0	405
Proceeds from revolving line of credit	0	128,500
Repayments of revolving line of credit	0	(128,500)
Principal payments of long-term obligations	(4,069)	(3,750)
Purchase of company stock	0	(12,315)
Net cash used in financing activities	(4,727)	(6,885)
Net increase (decrease) in cash and cash equivalents	35,917	(18,587)
Cash and cash equivalents at beginning of period	30,197	27,502
Cash and cash equivalents at end of period	66,114	8,915
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	2,188	2,276
Cash paid for income taxes, net of refunds received	$ 315	$ 758